A combination therapy using anti PD-1 antibody Nivolumab and anti CTLA-4 antibody ipilimumab resulted in tumor remission in 29% of patients with HCC within 6 weeks of treatment (Table 3) (133, 137). This evidence concerns the gene CTLA4 and neoplasm.